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Clinical and laboratory characteristics of 39 patients with adult onset subacute sclerosing panencephalitis
(SSPE) are described and compared to those of juvenile onset patients regarding preceding measles, age
at onset, gender, interval between onset and diagnosis, clinical profile, and course during follow up.
Diagnosis was based on clinical and electroencephalographic findings and raised anti-measles antibody
titres in cerebrospinal fluid. Mean age at SSPE symptom onset was 20.9¡4.9 years and mean interval
from onset to diagnosis was 6.3¡9.6 months. Referral diagnosis was accurate in only 12 patients.
Presenting symptoms included myoclonus, behavioural changes, seizures, and cognitive, visual, and
extrapyramidal disturbance. All patients received symptomatic therapy; 19 also received disease
modifying agents. Five of seven pregnant women had successful deliveries. The follow-up period varied
widely (maximum 60 months, median 9 months). The profile of adult onset SSPE did not differ from the
rest of the cohort, except for a longer interval between measles infection and symptom onset (p,0.0001).
SSPE in adults poses diagnostic challenges for clinicians. A high index of suspicion and appropriate
investigations are necessary for early diagnosis and counselling.
S
ubacute sclerosing panencephalitis (SSPE) is attributed
to infection by mutated measles virus and is charac-
terised by progressive mental deterioration, motor
decline, and myoclonus leading to death within 1–3 years
of onset. SSPE is essentially a disease of childhood and
commonly occurs at 5–15 years of age. The introduction of
measles vaccination under mass immunisation programs has
led to a significant fall in the incidence of measles and SSPE
throughout the world. Although the mean age at onset of
SSPE has been reported to be increasing,1 the literature
regarding adult onset SSPE remains rather sparse.2–8 This
report, therefore, describes various demographic, clinical, and
laboratory features of adult onset (over 18 years of age) SSPE
patients.
METHODS
This retrospective study was conducted at the National
Institute of Mental Health and Neuro Sciences
(NIMHANS), Bangalore, a tertiary care university teaching
hospital in South India and involved 307 SSPE patients
evaluated during the period January 1995 to December 2004.
Diagnosis was based on the characteristic clinical features of
progressive cognitive and/or behavioural changes, myoclo-
nus, electroencephalographic evidence of periodic complexes,
and raised IgG (>1:25) anti-measles antibody in cere-
brospinal fluid (CSF), detected by ELISA in all patients.
This cut-off CSF titre was established in our neurovirology
laboratory after evaluation in 1986–87 of over 300 CSF
samples obtained from patients with neurological illnesses
other than SSPE (brain tumours, head injuries, other CNS
infections) and individuals undergoing spinal anaesthesia for
minor surgical procedures.9 Analysis for oligoclonal bands in
CSF was not carried out. We have not performed any specific
test to determine disruption of the blood-brain barrier;
however, during the 1980s and 1990s we carried out
oligoclonal antibody banding in some patients which showed
that anti-measles antibodies in the CSF were indeed due to
intrathecal production and not caused by passive transfer of
antibodies as a result of disruption of the blood-brain
barrier.10
Thirty nine patients aged 18 years and above at first
symptom onset were considered to have adult onset SSPE
and their data regarding measles vaccination, any history of
measles, age at onset of symptoms and diagnosis, presenting
symptoms, initial diagnosis, clinical staging, course of the
disease, electroencephalographic changes, and measles anti-
body status were recorded.
SPSS v10 software was used for statistical analysis.
Student’s t test and Pearson x2 test were applied to compare
various parameters. Data were considered significant for p
values less than 0.05 (p(0.05).
RESULTS
Demographic profi le
Most (82%) patients (n = 307) in this cohort were from
South India (fig 1), as were most patients with adult onset
SSPE (n = 32). However, a few patients were from eastern
India (n = 5) and other parts of the country (n = 2) (fig 1). Of
these 307 patients, 39 (12.7%; 25 males, 14 females)
experienced the first symptoms of SSPE after 18 years of
age, the mean age at onset of symptoms being
20.9¡4.9 years (range: 18–43 years). Mean age at diagnosis
was 21.3¡5.1 years and ranged widely from 18 to 43 years.
The interval between the onset of symptoms and diagnosis
was 6.3¡9.6 months (range: 0.3–60 months). A history of
measles was available for 13 of 34 patients where the
information was recorded. Symptoms of SSPE were noted at
a mean interval of 16.7¡6.3 years (range: 8–33 years)
following measles infection.
Clinical profi le
The referral diagnosis was SSPE in 12 patients, while in
others it varied widely and included psychosis, complex
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partial seizures, viral retinitis, rheumatic chorea, seizure
disorder, vasculitis, neurometabolic syndrome, extrapyrami-
dal syndrome, and juvenile myoclonic epilepsy. The mean
interval between the first symptom and evaluation at our
centre was much longer (13.1¡25.4 months) in patients
with an inaccurate diagnosis compared to patients with the
correct diagnosis (4.8¡4.9 months, p = 0.27).
The presenting manifestations were myoclonus (25),
behavioural changes (five), seizures (three), cognitive
impairment (two), visual disturbances (two), and extrapyr-
amidal symptoms (two). Myoclonus characteristically was
slow and was the initial feature in 64.1% of patients.
However, during the course of the disease, all patients
developed myoclonus involving limb and axial musculature.
Myoclonus was asymmetrical in 11 patients (28.2%).
Eighteen patients had gait abnormality and falls probably
due to myoclonus. The behavioural and cognitive symptoms
consisted of poor academic performance, forgetfulness,
recent change in personality, dullness, and apathy. Seven
patients had pyramidal weakness (four on the right and three
on the left). Two patients presented with impaired vision.
However, during the course of the disease, two additional
patients also developed visual symptoms. One patient was
blind from birth due to bilateral micro cornea and coloboma.
A total of nine patients had seizures during the course of the
illness (two partial and seven secondary generalised), in
three of whom it was the initial manifestation. No patient
had status epilepticus. Tremors were reported at onset in two
patients and appendicular dystonia was subsequently noted
in three patients.
Seven of the 14 women were pregnant. Four patients had
onset of symptoms during pregnancy and one patient had
worsening of symptoms during pregnancy. Two patients
conceived after the diagnosis of SSPE was established. Of
these seven patients, five had a successful delivery; details
regarding the outcome of delivery were not available in the
other two patients.
Imaging
Imaging studies were carried out at some time during the
course of the illness in all but two patients (computed
tomography (CT) in 26 and magnetic resonance imaging
(MRI) in 12). The interval between the onset of symptoms
and CT imaging ranged from 1 month to 4 years (mean:
5.5¡9.2 months). Fourteen patients had normal CT con-
ducted between 1 month and 1 year after symptom onset. In
others, the CT changes were as follows: white matter
hypodensities involving frontal/parietal/occipital/temporal
regions (two), cerebral atrophy (six), thalamic hypodensities
(one), and diffuse oedema (two) (fig 2A). MRI was carried
out in 12 patients between 1 month and 4 years (mean:
9.3¡13.2 months) after the onset of symptoms. Seven
patients had normal MRI conducted between 2 and
18 months after the onset of symptoms. In the remaining
five patients, the MRI abnormalities included focal or diffuse
white matter signal changes in three patients and cerebral
atrophy of varying degrees in the other two (fig 2B).
Laboratory studies
All patients underwent CSF analysis at NIMHANS at a mean
interval of 7.1¡10.2 months (range: 2 weeks to 60 months)
after the first symptom. The results were as follows: glucose
58.8¡10.5 mg/dl (range: 38–78 mg/dl), protein
39.6¡21.9 mg/dl (range: 10–96 mg/dl), and cells
1.9¡2.7 cells/mm3 (range: 0–9 cells/mm3). Fourteen patients
had raised CSF protein levels of .45 mg/dl and four patients
had pleocytosis (.5 cells/mm3). ELISA was used for estima-
tion of anti-measles antibody and the diagnostic titre of
>1:25 was observed in all patients. Simultaneous estimation
of anti-measles antibody in the serum was carried out in 22/
39 patients. The ratios of serum to CSF anti-measles antibody
in these patients ranged from 1 to 10.
Follow up
Nineteen patients were treated with disease modifying agents
for variable periods of time: isoprinosine (12), intravenous
immunoglobulin (two), oral steroids (six), levamisole (five),
amantadine (seven), methylprednisolone (one), and plasma-
pheresis (one). All patients also received symptomatic
treatment for myoclonus and seizures. The follow-up period
from the onset of symptoms was variable: 1 year or less in 27
patients; 1–2 years in eight, 2–3 years in two, and 38 months
and 60 months in one patient each (mean:
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Figure 1 Map showing the demographic profile of adult onset SSPE
patients and the entire cohort of SSPE patients.
Figure 2 (A) Non-contrast axial section of computed tomography brain
image showing white matter hypodensity in a 20 year old patient
1 month after symptom onset. (B) Axial section of T1W magnetic
resonance image of a 22 year old patient showing diffuse atrophy
48 months after symptom onset.
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11.1¡11.4 months). There was no subjective difference in
the outcome between untreated and treated groups.
However, evaluation did not include any objective mea-
sures/scales.
Comparison with childhood onset SSPE
The data on adult onset SSPE were compared with that of the
rest of the cohort as regards age at onset, interval from onset
to diagnosis, gender distribution, interval between measles
infection and onset of symptoms, clinical symptoms, and
duration of follow up. There was no significant difference in
any of these parameters between the two groups, except that
the interval between measles infection and onset of
symptoms on Student’s t test (p,0.0001) was longer in the
adult onset group (table 1). Onset of symptoms among all
evaluated SSPE patients showed peak incidence between 9
and 14 years of age. In the adult onset cases, most patients
(n = 28) developed symptoms at or before 20 years of age
(fig 3).
DISCUSSION
Subacute sclerosing panencephalitis is a prototype neurode-
generative disease of childhood characterised by onset of
neurological symptoms between 5 and 15 years of age with a
progressive downhill course leading to death within 2–
4 years.1 The incidence of adult onset SSPE has been reported
to vary between 1–1.75% and 2.6%.11 12 To date less than 100
cases of adult onset SSPE have been published in the
literature, the majority being case reports2 3 6–8 13 14 baring one
exception.4 The present series of 39 patients constituted
12.7% of the cohort evaluated over a decade at our centre. To
the best of our knowledge this is the largest series of adult
onset SSPE patients. Most of our patients were from South
India; whether a similar incidence of adult onset cases of
SSPE is observed elsewhere in India is not known.
Tan et al4 reported eight cases of adult onset SSPE
(>18 years) seen between 1980 and 1987 at a university
hospital in Turkey. Age at onset was between 18 and
24 years, with a 1–9 month interval between first symptoms
and diagnosis. In the published literature on adult onset
SSPE, the age at onset was 20–35 years with a mean delay in
diagnosis of 10.6 months.5 A similar time lag of
6.3¡9.6 months in diagnosis was observed in the present
study. In childhood onset SSPE, boys are more frequently
affected,1 while in adults the gender distribution is reported
to be equal.4 5 However, in our series there was a preponder-
ance of males (25 males, 14 females) (table 2).
Singer et al5 have suggested that adult onset SSPE patients
get measles either at a very early age (,3 years) or at an
unusually late age (.9 years). However, this was not noted
either by us or by Tan et al.4 A history of prior infection of
measles in childhood was available in 13 patients in our
series and the interval of 16.7¡6.3 years between measles
infection and the onset of neurological symptoms was
significantly longer compared with paediatric onset SSPE
(p,0.0001). The age at measles infection among these
patients was 1 year (two), 3 years (two), 4 years (one),
5 years (four), and 10 years (two).
Certain differences have been recorded between adult
onset and childhood onset SSPE. Singer et al5 observed that
only two of 13 adult onset patients presented with
personality change, while eight had purely ophthalmic
manifestations. In the current series, 32 patients presented
with either cognitive and behavioural changes or myoclonus
and only two had ophthalmic symptoms at onset.
Tan et al4 noted that two out of four women had their first
manifestations of SSPE during pregnancy. In the present
series, four out of seven women who conceived had onset of
symptoms during the course of pregnancy or during
puerperium. During pregnancy specific and innate immune
systems are altered for adaptation to foreign antigens of the
fetus and placenta. The immunosuppressant agents or cells
produced by the fetus, such as fetal suppressor T cells, alpha-
fetoprotein, and lymphokines, enter the maternal circulation
and modify cell mediated immunity. This suppression of cell
mediated immunity may lead to more severe virus infection
either in the mother or in the fetus. Influenza, hepatitis E,
polioviruses, and chicken pox are associated with increased
severity of maternal illness during pregnancy, whereas
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Figure 3 Bar diagram showing age distribution of patients with SSPE.
Table 1 Comparison between adult onset and
paediatric onset SSPE
Parameter
Adult onset
(>18 years)
Paediatric onset
(,18 years) p
Number of patients 39 268 –
Male/female 25/14 202/66 0.11
Age at onset, years 20.9¡4.9 10.5¡3.6 0.0001*
Duration from onset to 6.3¡9.6 5.6¡8.5 0.68
diagnosis, months
Interval between measles 16.7¡6.3 7.4¡3.5 0.0001*
and symptoms, years (n = 13) (n = 96)
Myoclonus 39 249 0.1
Lateralising deficits 7 53 0.33
Visual disturbances 5 23 0.4
Seizures 9 93 0.14
Follow-up duration, 11.1¡11.4 12.9¡23.8 0.64
months
*Significantly correlated on Student’s t test.
Table 2 Comparison between various published adult
onset SSPE case series
Parameter Tan et al4 Singer et al5 Present series
Number of cases 8 13 39
Study period 1980–1987 1965–1997 1995–2004
Design Retrospective Case reviews Retrospective
Mean age, years 19.6 25.4 20.9
(range) (18–24) (20–35) (18–43)
Gender (M/F) 4/4 7/6 25/14
History of measles 5 5 13
Duration of symptoms 1–9 NA 6.3¡9.6
before diagnosis,
months
Follow-up duration, 7–38 8–32 1–60
months
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rubella, parvovirus, cytomegalovirus, herpes simplex, and
human immunodeficiency virus are associated with
increased fetal damage.15 However, whether pregnancy
precipitates or modifies the natural course of SSPE remains
to be established.
The course of adult onset SSPE is not clearly known due to
the paucity of reports in the literature. It is generally
postulated that SSPE has an aggressive course in adults.13 16
Tan et al4 reported that all but one of seven patients died
within 1 year of symptom onset. They proposed that survival
of patients with SSPE becomes shorter with increasing age at
onset. However, Singer et al5 observed a mean survival period
of 24 months (range: 8 months to 6 years) with three
patients surviving for more than 3 years. They believe that
patients in the adult onset group have a higher rate of
spontaneous remission and favourable response to disease
modifying agents. In the present series, the median duration
of follow up was only 9 months and therefore it is not
possible to comment on the length of patient survival.
CONCLUSIONS
What governs the interval between the occurrence of measles
and the onset of SSPE? Whether the low virulence of mutated
measles virus or the immunological status of the host
accounts for late occurrence needs to be explored. This
retrospective study and observations by others suggest that
SSPE occurs in adults and may follow a much earlier measles
infection. A high index of suspicion may be required during
initial stages of the disease for early diagnosis, proper
counselling, and therapeutic intervention. Descriptions of
similar cases, long term follow up, and research into the
agent and host factors in adult onset SSPE may improve our
knowledge regarding the pathophysiology of this preventable
disease.
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